{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:56:01Z","timestamp":1791114961825,"version":"4.1.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acute lymphoblastic leukemia (ALL) in adult patients is often resistant to current therapy, making the development of novel therapeutic agents paramount. We investigated whether mTOR inhibitors (MTIs), a class of signal transduction inhibitors, would be effective in primary human ALL. Lymphoblasts from adult patients with precursor B ALL were cultured on bone marrow stroma and were treated with CCI-779, a second generation MTI. Treated cells showed a dramatic decrease in cell proliferation and an increase in apoptotic cells, compared to untreated cells. We also assessed the effect of CCI-779 in a NOD\/SCID xenograft model. We treated a total of 68 mice generated from the same patient samples with CCI-779 after establishment of disease. Animals treated with CCI-779 showed a decrease in peripheral-blood blasts and in splenomegaly. In dramatic contrast, untreated animals continued to show expansion of human ALL. We performed immunoblots to validate the inhibition of the mTOR signaling intermediate phospho-S6 in human ALL, finding down-regulation of this target in xenografted human ALL exposed to CCI-779. We conclude that MTIs can inhibit the growth of adult human ALL and deserve close examination as therapeutic agents against a disease that is often not curable with current therapy.<\/jats:p>","DOI":"10.1182\/blood-2005-05-1935","type":"journal-article","created":{"date-parts":[[2005,9,29]],"date-time":"2005-09-29T20:24:07Z","timestamp":1128025447000},"page":"1149-1155","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":148,"title":["The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL"],"prefix":"10.1182","volume":"107","author":[{"given":"David T.","family":"Teachey","sequence":"first","affiliation":[{"name":"From the Division of Oncology, Department of Pediatrics, and the Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, PA; the Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA; and the Department of Molecular Pharmacology, St Jude Children's Research Hospital, Memphis, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana A.","family":"Obzut","sequence":"additional","affiliation":[{"name":"From the Division of Oncology, Department of Pediatrics, and the Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, PA; the Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA; and the Department of Molecular Pharmacology, St Jude Children's Research Hospital, Memphis, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Cooperman","sequence":"additional","affiliation":[{"name":"From the Division of Oncology, Department of Pediatrics, and the Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, PA; the Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA; and the Department of Molecular Pharmacology, St Jude Children's Research Hospital, Memphis, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Fang","sequence":"additional","affiliation":[{"name":"From the Division of Oncology, Department of Pediatrics, and the Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, PA; the Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA; and the Department of Molecular Pharmacology, St Jude Children's Research Hospital, Memphis, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Carroll","sequence":"additional","affiliation":[{"name":"From the Division of Oncology, Department of Pediatrics, and the Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, PA; the Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA; and the Department of Molecular Pharmacology, St Jude Children's Research Hospital, Memphis, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Choi","sequence":"additional","affiliation":[{"name":"From the Division of Oncology, Department of Pediatrics, and the Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, PA; the Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA; and the Department of Molecular Pharmacology, St Jude Children's Research Hospital, Memphis, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Houghton","sequence":"additional","affiliation":[{"name":"From the Division of Oncology, Department of Pediatrics, and the Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, PA; the Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA; and the Department of Molecular Pharmacology, St Jude Children's Research Hospital, Memphis, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie I.","family":"Brown","sequence":"additional","affiliation":[{"name":"From the Division of Oncology, Department of Pediatrics, and the Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, PA; the Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA; and the Department of Molecular Pharmacology, St Jude Children's Research Hospital, Memphis, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan A.","family":"Grupp","sequence":"additional","affiliation":[{"name":"From the Division of Oncology, Department of Pediatrics, and the Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, PA; the Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA; and the Department of Molecular Pharmacology, St Jude Children's Research Hospital, Memphis, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111712002477800_REF1","doi-asserted-by":"crossref","unstructured":"Gokbuget N, Hoelzer D. Recent approaches in acute lymphoblastic leukemia in adults. Rev Clin Exp Hematol. 2002;6: 114-141.","DOI":"10.1046\/j.1468-0734.2002.00068.x"},{"key":"2019111712002477800_REF2","doi-asserted-by":"crossref","unstructured":"Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer. 2004;100: 657-666.","DOI":"10.1002\/cncr.20026"},{"key":"2019111712002477800_REF3","doi-asserted-by":"crossref","unstructured":"Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 2005;16: 525-537.","DOI":"10.1093\/annonc\/mdi113"},{"key":"2019111712002477800_","doi-asserted-by":"crossref","unstructured":"Schreiber SL. Chemistry and biology of immunophilins and their immunosuppressive ligands. Science. 1991;251: 283-287.","DOI":"10.1126\/science.1702904"},{"key":"2019111712002477800_REF5","doi-asserted-by":"crossref","unstructured":"Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int. 2001;59: 3-16.","DOI":"10.1046\/j.1523-1755.2001.00460.x"},{"key":"2019111712002477800_REF6","doi-asserted-by":"crossref","unstructured":"Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic, II: fermentation, isolation and characterization. J Antibiot. 1975;28: 727-732.","DOI":"10.7164\/antibiotics.28.727"},{"key":"2019111712002477800_REF7","doi-asserted-by":"crossref","unstructured":"Calne RY, Collier DS, Lim S, et al. Rapamycin for immunosuppression in organ allografting [letter]. Lancet. 1989;2: 227.","DOI":"10.1016\/S0140-6736(89)90417-0"},{"key":"2019111712002477800_REF8","doi-asserted-by":"crossref","unstructured":"Eng CP, Sehgal SN, Vezina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot. 1984;37: 2131-1237.","DOI":"10.7164\/antibiotics.37.1231"},{"key":"2019111712002477800_","doi-asserted-by":"crossref","unstructured":"Douros J, Suffness M. New antitumor substances of natural origin. Cancer Treat Rev. 1981;8: 63-87.","DOI":"10.1016\/S0305-7372(81)80006-0"},{"key":"2019111712002477800_REF10","doi-asserted-by":"crossref","unstructured":"Yu K, Torak-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer. 2001;8: 249-258.","DOI":"10.1677\/erc.0.0080249"},{"key":"2019111712002477800_REF11","doi-asserted-by":"crossref","unstructured":"Brown VI, Fang J, Alcorn K, et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci U S A. 2003;100: 15113-15118.","DOI":"10.1073\/pnas.2436348100"},{"key":"2019111712002477800_REF12","doi-asserted-by":"crossref","unstructured":"Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer. 2004;91: 1420-1424.","DOI":"10.1038\/sj.bjc.6602162"},{"key":"2019111712002477800_","doi-asserted-by":"crossref","unstructured":"Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004;22: 2336-2347.","DOI":"10.1200\/JCO.2004.08.116"},{"key":"2019111712002477800_","unstructured":"Peralba JM, DeGraffenried L, Friedrichs W, et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res. 2003;9: 2887-2892."},{"key":"2019111712002477800_REF15","doi-asserted-by":"crossref","unstructured":"Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22: 909-918.","DOI":"10.1200\/JCO.2004.08.185"},{"key":"2019111712002477800_REF16","unstructured":"Kumagai M, Manabe A, Coustan-Smith E, et al. Use of stroma-supported cultures of leukemic cells to assess antileukemic drugs, II: potent cytotoxicity of 2-chloro-deoxyadenosine in acute lymphoblastic leukemia. Leukemia. 1994;8: 1116-1123."},{"key":"2019111712002477800_REF17","doi-asserted-by":"crossref","unstructured":"Baersch G, Mollers T, Hotte A, et al. Good engraftment of B-cell precursor ALL in NOD-SCID mice. Klin Padiatr. 1997;209: 178-185.","DOI":"10.1055\/s-2008-1043947"},{"key":"2019111712002477800_REF18","doi-asserted-by":"crossref","unstructured":"Consolini R, Pui CH, Behm FG, Raimondi SC, Campana D. In vitro cytotoxicity of docetaxel in childhood acute leukemias. J Clin Oncol. 1998;16: 907-913.","DOI":"10.1200\/JCO.1998.16.3.907"},{"key":"2019111712002477800_REF19","doi-asserted-by":"crossref","unstructured":"Ek O, Gaynon P, Zeren T, Chelstrom LM, Myers DE, Uckun FM. Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase. Leuk Lymphoma. 1997;31: 143-149.","DOI":"10.3109\/10428199809057594"},{"key":"2019111712002477800_REF20","doi-asserted-by":"crossref","unstructured":"Borgmann A, Baldy C, von Stackelberg A, et al. Childhood ALL blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD\/SCID mice. Pediatr Hematol Oncol. 2000;17: 635-650.","DOI":"10.1080\/08880010050211349"},{"key":"2019111712002477800_REF21","doi-asserted-by":"crossref","unstructured":"Umiel T, Friedman S, Zaizov R, et al. Long-term culture of infant leukemia cells: dependence upon stromal cells from the bone marrow and bilineage differentiation. Leuk Res. 1986;10: 1007-1013.","DOI":"10.1016\/0145-2126(86)90253-5"},{"key":"2019111712002477800_REF22","doi-asserted-by":"crossref","unstructured":"Liem NL, Papa RA, Milross CG, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood. 2004;103: 3905-3914.","DOI":"10.1182\/blood-2003-08-2911"},{"key":"2019111712002477800_REF23","doi-asserted-by":"crossref","unstructured":"Barker J, Verfaillie CM. A novel in vitro model of early human adult B lymphopoiesis that allows proliferation of pro-B cells and differentiation to mature B lymphocytes. Leukemia. 2000;14: 1614-1620.","DOI":"10.1038\/sj.leu.2401869"},{"key":"2019111712002477800_REF24","doi-asserted-by":"crossref","unstructured":"Huang S, Shu L, Easton J, et al. Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. J Biol Chem. 2004;279: 36490-36496.","DOI":"10.1074\/jbc.M401208200"},{"key":"2019111712002477800_REF25","doi-asserted-by":"crossref","unstructured":"Cooperman J, Neely R, Teachey DT, Grupp S, Choi JK. Cell division rates of primary human precursor B cells in culture reflect in vivo rates. Stem Cells. 2004;22: 1111-1120.","DOI":"10.1634\/stemcells.22-6-1111"},{"key":"2019111712002477800_REF26","unstructured":"Hosoi H, Dilling MB, Shikata T, et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res. 1999;59: 886-894."},{"key":"2019111712002477800_REF27","doi-asserted-by":"crossref","unstructured":"Calastretti A, Rancati F, Ceriani MC, Asnaghi L, Canti G, Nicolin A. Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect. Eur J Cancer. 2001;37: 2121-2128.","DOI":"10.1016\/S0959-8049(01)00256-8"},{"key":"2019111712002477800_REF28","doi-asserted-by":"crossref","unstructured":"Calastretti A, Bevilacqua A, Ceriani C, et al. Damaged microtubules can inactivate BCL-2 by means of the mTOR kinase. Oncogene. 2001;20: 6172-6180.","DOI":"10.1038\/sj.onc.1204751"},{"key":"2019111712002477800_REF29","doi-asserted-by":"crossref","unstructured":"Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000;103: 253-262.","DOI":"10.1016\/S0092-8674(00)00117-3"},{"key":"2019111712002477800_","doi-asserted-by":"crossref","unstructured":"Kawasome H, Papst P, Webb S, et al. Targeted disruption of p70(s6k) defines its role in protein synthesis and rapamycin sensitivity. Proc Natl Acad Sci U S A. 1998;95: 5033-5038.","DOI":"10.1073\/pnas.95.9.5033"},{"key":"2019111712002477800_REF31","doi-asserted-by":"crossref","unstructured":"Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene. 2000;19: 6680-6686.","DOI":"10.1038\/sj.onc.1204091"},{"key":"2019111712002477800_REF32","doi-asserted-by":"crossref","unstructured":"Jefferies HB, Reinhard C, Kozma SC, Thomas G. Rapamycin selectively represses translation of the \u201cpolypyrimidine tract\u201d mRNA family. Proc Natl Acad Sci U S A. 1994;91: 4441-4445.","DOI":"10.1073\/pnas.91.10.4441"},{"key":"2019111712002477800_REF33","doi-asserted-by":"crossref","unstructured":"Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res. 2005;65: 2825-2831.","DOI":"10.1158\/0008-5472.CAN-04-3137"},{"key":"2019111712002477800_REF34","doi-asserted-by":"crossref","unstructured":"Plasschaert SL, Kamps WA, Vellenga E, de Vries EG, de Bont ES. Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation? Cancer Treat Rev. 2004;30: 37-51.","DOI":"10.1016\/S0305-7372(03)00140-3"},{"key":"2019111712002477800_REF35","doi-asserted-by":"crossref","unstructured":"Ettenger RB, Grimm EM. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am J Kidney Dis. 2001;38: S22-S28.","DOI":"10.1053\/ajkd.2001.27838"},{"key":"2019111712002477800_REF36","doi-asserted-by":"crossref","unstructured":"Levis M, Pham R, Smith BD, Small D. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood. 2004;104: 1145-1150.","DOI":"10.1182\/blood-2004-01-0388"},{"key":"2019111712002477800_REF37","doi-asserted-by":"crossref","unstructured":"Millar JL, Millar BC, Powles RL, et al. Liposomal vincristine for the treatment of human acute lymphoblastic leukaemia in severe combined immunodeficient (SCID) mice. Br J Haematol. 1998;102: 718-721.","DOI":"10.1046\/j.1365-2141.1998.00831.x"},{"key":"2019111712002477800_REF38","doi-asserted-by":"crossref","unstructured":"Nijmeijer BA, Willemze R, Falkenburg JH. An animal model for human cellular immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD\/scid mice. Blood. 2002;100: 654-660.","DOI":"10.1182\/blood.V100.2.654"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/3\/1149\/1280891\/zh800306001149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/3\/1149\/1280891\/zh800306001149.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T20:08:25Z","timestamp":1586462905000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/3\/1149\/22148\/The-mTOR-inhibitor-CCI779-induces-apoptosis-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,1]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,2,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-05-1935","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,1]]}}}